FDA tracker: Novel approvals in pediatrics during 2026

Multiple strides in pediatric care have been reported so far in 2026, marking a transformative year for the treatment of rare pediatric disorders and chronic dermatologic conditions. From the first targeted therapy for neurologic complications in Hunter syndrome and novel interventions for ultrarare diseases such as Menkes disease and arginase 1 deficiency, to historic firsts in oral and topical treatments for plaque psoriasis and atopic dermatitis in children and adolescents, clinical innovation is rapidly expanding the therapeutic tool kit available to pediatricians.

These clinical advancements emphasize a continued shift toward targeted therapy, with new intravenous, subcutaneous, oral, and topical formulations designed to address underlying disease drivers, improve clinical outcomes, and enhance patient quality of life. The following is a comprehensive recap of the novel drugs approved by the FDA in 2026 for use in patients younger than 18 years.

Novel drug approvals recap: 2026

1. Copper histidinate (Zycubo; Sentynl Therapeutics Inc)
Date: January 12, 2026
Indication: To manage Menkes disease in children

Background: Based on dedicated pediatric data from 2 open-label, single-arm clinical trials evaluating this subcutaneous formulation against an external control group, patients initiating treatment within 4 weeks of birth demonstrated a 78% reduction in the risk of death. This introduces the first approved treatment for this ultrarare degenerative disorder, offering a critical subcutaneous clinical option that bypasses defective intestinal copper absorption.¹

Related coverage: FDA approves Zycubo for treatment of Menkes disease in children

2. Difamilast (Adquey; Acrotech Biopharma)
Date: February 12, 2026
Indication: For treating mild to moderate atopic dermatitis in pediatric patients 2 years and older

Background: Based on data from a pivotal phase 3 clinical trial in pediatric patients (NCT04052386), twice-daily application of the 1% ointment achieved statistically significant improvements in Investigator’s Global Assessment scores compared with vehicle at week 4. This new nonsteroidal PDE4 inhibitor offers a twice-daily therapeutic alternative for patients inadequately controlled by or intolerant to existing topical corticosteroids or other inhibitors such as crisaborole.²

Relevant coverage: FDA approves difamilast as new topical PDE4 inhibitor for atopic dermatitis

3. Pegzilarginase-nbln (Loargys; Immedica Pharma)
Date: February 23, 2026
Indication: To treat hyperargininemia in adult and pediatric patients 2 years and older with arginase 1 deficiency

Background: Based on demonstrated reductions in plasma arginine—the primary driver of spasticity and developmental delay in this population—the approval provides the first disease-modifying enzyme therapy to be used in conjunction with dietary protein restriction. For pediatricians, this introduces a targeted approach for a progressive metabolic disorder often diagnosed in early childhood, replacing a previous reliance on strictly symptomatic management.³

Relevant coverage: US FDA has granted accelerated approval of Loargys for hyperargininemia

4. Navepegritide (Yuviwel; Ascendis Pharma)
Date: February 27, 2026
Indication: For increasing linear growth in children 2 years and older with achondroplasia with open epiphyses

Background: Based on dedicated pediatric data from 3 randomized, placebo-controlled trials, including the pivotal ApproaCH trial (NCT05598320), the once-weekly administered prodrug demonstrated clinical benefit through an improvement in annualized growth velocity. As the first and only once-weekly treatment indicated for children 2 years and older with open epiphyses, navepegritide offers a new, practical administration option that provides continuous systemic exposure to counteract overactive FGFR3 signaling.⁴

Related coverage: FDA issues historic approval for navepegritide in achondroplasia

5. Icotrokinra (Icotyde; Janssen Biotech)
Date: March 17, 2026
Indication: For the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 12 years and older weighing at least 40 kg

Background: Based on the phase 3 ICONIC program, which included the dedicated ICONIC-LEAD trial (NCT06095115) of approximately 2500 patients 12 years and older, 65% of treated patients achieved an Investigator’s Global Assessment score of 0 or 1 at 16 weeks, with the adolescent subgroup notably outperforming the overall population with an 86.4% IGA 0/1 response at week 24. This first-in-class, once-daily oral targeted peptide offers a systemic alternative to injectable biologics for patients 12 years and older.⁵

Relevant coverage: FDA approves icotrokinra, first oral targeted peptide for plaque psoriasis

6. Tividenofusp alfa-eknm (Avlayah; Denali Therapeutics)
Date: March 24, 2026
Indication: To treat the neurological manifestations of Hunter syndrome in pediatric patients

Background: Based on a dedicated pediatric phase 1/2 open-label trial (NCT04251026) involving 47 patients aged 3 months to 13 years, the once-weekly intravenous infusion significantly reduced cerebrospinal fluid heparan sulfate, yielding a 91% average decrease from baseline at 24 weeks. This marks the first targeted therapy specifically approved for the neurologic complications of this rare X-linked disorder, providing a critical new intervention that must be initiated before a child develops advanced neurologic impairment.⁶

Related coverage: FDA approves Avlayah for Hunter syndrome

References

1. FDA approves first treatment for children with Menkes disease. News release. FDA. January 12, 2026. Accessed March 31, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-menkes-disease
2. Acrotech Biopharma Inc. announces FDA approval of Adquey (difamilast 1%) ointment for the treatment of mild-to-moderate atopic dermatitis. News release. Acrotech Biopharma. February 13, 2026. Accessed April 8, 2026. https://www.aurobindo.com/api/uploads/corporateannouncements/Adquey-(Difamilast)_NDA%20Approval_PressRelease_13-Feb-26.pdf
3. US FDA has granted accelerated approval of Loargys (pegzilarginase-nbln) for the treatment of hyperargininemia in patients 2 years and older witharginase 1 deficiency (ARG1-D). News release. Immedica Pharma. February 23, 2026. Accessed April 8, 2026. https://www.immedica.com/en/press/us-fda-has-granted-accelerated-approval-loargysr-pegzilarginase-nbln-treatment
4. Ascendis Pharma. FDA approves once-weekly YUVIWEL (navepegritide) for children with achondroplasia aged 2 years and older. News release. Ascendis Pharma. February 27, 2026. Accessed March 31, 2026. https://investors.ascendispharma.com/news-releases/news-release-details/fda-approves-once-weekly-yuviwelr-navepegritide-children
5. Johnson & Johnson. FDA approves ICOTYDE (icotrokinra), the first and only targeted oral peptide IL-23 receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis. News release. Johnson & Johnson. March 18, 2026. Accessed March 31, 2026. https://www.jnj.com/media-center/press-releases
6. FDA approves drug to treat neurologic manifestations of Hunter syndrome. News release. FDA. March 25, 2026. Accessed March 31, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome?utm_medium=email&utm_source=govdelivery